OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
Sung‐Ho Kim, Jung-hwa Yoo, Woo Je Lee, et al.
Diabetes & Metabolism Journal (2016) Vol. 40, Iss. 5, pp. 339-339
Open Access | Times Cited: 52
Sung‐Ho Kim, Jung-hwa Yoo, Woo Je Lee, et al.
Diabetes & Metabolism Journal (2016) Vol. 40, Iss. 5, pp. 339-339
Open Access | Times Cited: 52
Showing 26-50 of 52 citing articles:
Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition
Yaochen Xie, Qian Zhou, Qiaojun He, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 13, Iss. 6, pp. 2383-2402
Open Access | Times Cited: 7
Yaochen Xie, Qian Zhou, Qiaojun He, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 13, Iss. 6, pp. 2383-2402
Open Access | Times Cited: 7
Efficient integration of analytical quality-by-design and tri-hued HPLC-DAD approach for synchronized assessment of gemigliptin and rosuvastatin in their fixed-dose pills: Application to stability study
Sara M. Mohyeldin, Hoda G. Daabees, Wael Talaat, et al.
Sustainable Chemistry and Pharmacy (2024) Vol. 42, pp. 101777-101777
Closed Access | Times Cited: 1
Sara M. Mohyeldin, Hoda G. Daabees, Wael Talaat, et al.
Sustainable Chemistry and Pharmacy (2024) Vol. 42, pp. 101777-101777
Closed Access | Times Cited: 1
Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report
Hae Jin Kim, Young Sik Kim, Chang Beom Lee, et al.
Diabetes Therapy (2019) Vol. 10, Iss. 4, pp. 1271-1282
Open Access | Times Cited: 9
Hae Jin Kim, Young Sik Kim, Chang Beom Lee, et al.
Diabetes Therapy (2019) Vol. 10, Iss. 4, pp. 1271-1282
Open Access | Times Cited: 9
Divergent Reaction of Activated Pyridines with α,α-Difluorinated gem-Diols: Regioselective Synthesis of gem-Difluorinated Dihydropyridines and Dihydropyridones
Koushik Patra, Mallu Kesava Reddy, Sumitava Mallik, et al.
Organic Letters (2022) Vol. 24, Iss. 22, pp. 4014-4018
Closed Access | Times Cited: 6
Koushik Patra, Mallu Kesava Reddy, Sumitava Mallik, et al.
Organic Letters (2022) Vol. 24, Iss. 22, pp. 4014-4018
Closed Access | Times Cited: 6
Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression
Kyeong‐Min Lee, Yeo Jin Hwang, Gwon‐Soo Jung
Biochemical and Biophysical Research Communications (2022) Vol. 626, pp. 135-141
Closed Access | Times Cited: 6
Kyeong‐Min Lee, Yeo Jin Hwang, Gwon‐Soo Jung
Biochemical and Biophysical Research Communications (2022) Vol. 626, pp. 135-141
Closed Access | Times Cited: 6
Clinical Pharmacology of Dipeptidyl Peptidase 4 Inhibitors: Comparative Review
A.V. Sidorov Sidorov
Effective Pharmacotherapy (2020) Vol. 16, Iss. 25, pp. 24-48
Open Access | Times Cited: 6
A.V. Sidorov Sidorov
Effective Pharmacotherapy (2020) Vol. 16, Iss. 25, pp. 24-48
Open Access | Times Cited: 6
1,2,3‐Triazole analogs with bulky and conformationally rigid substructures: Synthesis and in vitro evaluation as DPP ‐4 inhibitors
Duy‐Viet Vo, Jong‐Kook Lee, Haeil Park
Bulletin of the Korean Chemical Society (2023) Vol. 44, Iss. 5, pp. 425-428
Closed Access | Times Cited: 2
Duy‐Viet Vo, Jong‐Kook Lee, Haeil Park
Bulletin of the Korean Chemical Society (2023) Vol. 44, Iss. 5, pp. 425-428
Closed Access | Times Cited: 2
Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus
Jaehyun Bae, You Jin Kim, Yongin Cho, et al.
Transplantation Proceedings (2019) Vol. 51, Iss. 10, pp. 3444-3448
Closed Access | Times Cited: 4
Jaehyun Bae, You Jin Kim, Yongin Cho, et al.
Transplantation Proceedings (2019) Vol. 51, Iss. 10, pp. 3444-3448
Closed Access | Times Cited: 4
<p>A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects</p>
Eunwoo Kim, Kyoung Ryun Park, In‐Jin Jang, et al.
Drug Design Development and Therapy (2019) Vol. Volume 13, pp. 3879-3885
Open Access | Times Cited: 4
Eunwoo Kim, Kyoung Ryun Park, In‐Jin Jang, et al.
Drug Design Development and Therapy (2019) Vol. Volume 13, pp. 3879-3885
Open Access | Times Cited: 4
The vasodilatory effect of gemigliptin via activation of voltage-dependent K+ channels and SERCA pumps in aortic smooth muscle
Hee Seok Jung, Mi Seon Seo, Jin Ryeol An, et al.
European Journal of Pharmacology (2020) Vol. 882, pp. 173243-173243
Closed Access | Times Cited: 4
Hee Seok Jung, Mi Seon Seo, Jin Ryeol An, et al.
European Journal of Pharmacology (2020) Vol. 882, pp. 173243-173243
Closed Access | Times Cited: 4
An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies
Mahanjit Konwar, Mitesh R. Maurya, Tushar Nishandar, et al.
Perspectives in Clinical Research (2021) Vol. 12, Iss. 3, pp. 159-164
Open Access | Times Cited: 4
Mahanjit Konwar, Mitesh R. Maurya, Tushar Nishandar, et al.
Perspectives in Clinical Research (2021) Vol. 12, Iss. 3, pp. 159-164
Open Access | Times Cited: 4
Financial Benefits of Renal Dose-Adjusted Dipeptidyl Peptidase-4 Inhibitors for Patients with Type 2 Diabetes and Chronic Kidney Disease
Hun Jee Choe, Yeh-Hee Ko, Sun Joon Moon, et al.
Endocrinology and Metabolism (2024) Vol. 39, Iss. 4, pp. 622-631
Open Access
Hun Jee Choe, Yeh-Hee Ko, Sun Joon Moon, et al.
Endocrinology and Metabolism (2024) Vol. 39, Iss. 4, pp. 622-631
Open Access
A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study)
Hae Jin Kim, Jung Hyun Noh, Min Kyong Moon, et al.
Journal of Diabetes Research (2024) Vol. 2024, pp. 1-10
Open Access
Hae Jin Kim, Jung Hyun Noh, Min Kyong Moon, et al.
Journal of Diabetes Research (2024) Vol. 2024, pp. 1-10
Open Access
Opportunities and challenges of incretins-based hypoglycemic agents treating of T2DM from the insight of physiological disposition
Yaochen Xie, Qiaojun He, Xiaoyi Wang, et al.
Authorea (Authorea) (2024)
Open Access
Yaochen Xie, Qiaojun He, Xiaoyi Wang, et al.
Authorea (Authorea) (2024)
Open Access
Gemigliptin, a potent selective dipeptidyl peptidase 4 inhibitor, protects endothelial progenitor cells by oxidative stress via caspase-3 dependent pathway
Mijung Lee, Amna Tariq, Manho Kim
Biochemistry and Biophysics Reports (2024) Vol. 38, pp. 101673-101673
Open Access
Mijung Lee, Amna Tariq, Manho Kim
Biochemistry and Biophysics Reports (2024) Vol. 38, pp. 101673-101673
Open Access
Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
Sangmo Hong, Chang Hee Jung, Song Han, et al.
Diabetes & Metabolism Journal (2021) Vol. 46, Iss. 1, pp. 63-70
Open Access | Times Cited: 3
Sangmo Hong, Chang Hee Jung, Song Han, et al.
Diabetes & Metabolism Journal (2021) Vol. 46, Iss. 1, pp. 63-70
Open Access | Times Cited: 3
Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers
Ignacio Conde-Carmona, Sandra García-Medina, Juan Manuel Jiménez-Vargas, et al.
Clinical Therapeutics (2018) Vol. 40, Iss. 10, pp. 1729-1740
Closed Access | Times Cited: 2
Ignacio Conde-Carmona, Sandra García-Medina, Juan Manuel Jiménez-Vargas, et al.
Clinical Therapeutics (2018) Vol. 40, Iss. 10, pp. 1729-1740
Closed Access | Times Cited: 2
Development and Validation of a Rapid and Sensitive Method for the Simultaneous Estimation of Gemigliptin and Teneligliptin in Bulk and Dosage Forms by Using Liquid Chromatography-tandem Mass Spectrometry
Amrish Chandra, Ramji Rathod, Faraat Ali, et al.
Current Pharmaceutical Analysis (2019) Vol. 16, Iss. 8, pp. 1104-1111
Closed Access | Times Cited: 2
Amrish Chandra, Ramji Rathod, Faraat Ali, et al.
Current Pharmaceutical Analysis (2019) Vol. 16, Iss. 8, pp. 1104-1111
Closed Access | Times Cited: 2
Effect of gemigliptin on cardiac ischemia/reperfusion and spontaneous hypertensive rat models
Dae-Hwan Nam, Jinsook Park, Sun-Hyun Park, et al.
Korean Journal of Physiology and Pharmacology (2019) Vol. 23, Iss. 5, pp. 329-329
Open Access | Times Cited: 2
Dae-Hwan Nam, Jinsook Park, Sun-Hyun Park, et al.
Korean Journal of Physiology and Pharmacology (2019) Vol. 23, Iss. 5, pp. 329-329
Open Access | Times Cited: 2
Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study
Sang Yong Kim, Sungrae Kim
Diabetes Therapy (2022) Vol. 14, Iss. 1, pp. 109-121
Open Access | Times Cited: 1
Sang Yong Kim, Sungrae Kim
Diabetes Therapy (2022) Vol. 14, Iss. 1, pp. 109-121
Open Access | Times Cited: 1
Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium–glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults
Sae Im Jeong, Yun Kim, Jae Jin Nah, et al.
British Journal of Clinical Pharmacology (2022) Vol. 89, Iss. 6, pp. 1780-1788
Open Access | Times Cited: 1
Sae Im Jeong, Yun Kim, Jae Jin Nah, et al.
British Journal of Clinical Pharmacology (2022) Vol. 89, Iss. 6, pp. 1780-1788
Open Access | Times Cited: 1
Effect of Dipeptidyl Peptidase- 4 (DPP-4) Inhibitor on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Nephropathy: A Randomized Controlled Trial
Thananda Trakarnvanich, Bancha Satirapoj, Sawangjit Suraamornkul, et al.
Research Square (Research Square) (2021)
Open Access | Times Cited: 1
Thananda Trakarnvanich, Bancha Satirapoj, Sawangjit Suraamornkul, et al.
Research Square (Research Square) (2021)
Open Access | Times Cited: 1
Pharmaceutical Applications of Organofluorine Compounds.19F NMR Fragment‐Based Discovery
Antonio Misale, Rodrigo J. Carbajo, José M. Cid, et al.
Patai's chemistry of functional groups (2023), pp. 1-31
Closed Access
Antonio Misale, Rodrigo J. Carbajo, José M. Cid, et al.
Patai's chemistry of functional groups (2023), pp. 1-31
Closed Access
The effect of gemigliptin treatment on immune parameters including regulatory T cells in patients with type 2 diabetes and moderate to very severe chronic renal impairment
Yanghyeon Kim, Nagyeom Lee, Sujung Heo, et al.
Medicine (2023) Vol. 102, Iss. 49, pp. e36455-e36455
Open Access
Yanghyeon Kim, Nagyeom Lee, Sujung Heo, et al.
Medicine (2023) Vol. 102, Iss. 49, pp. e36455-e36455
Open Access
Gemigliptin in Diabetic Kidney Disease in Asian Indians with Type 2 Diabetes in Real-Life Scenarios- Insights from Gem Study
Kiran Shah, SONALI A. PATANGE, Alka Gandhi
Integrative Diabetes and Cardiovascular Diseases (2019), pp. 76-83
Open Access
Kiran Shah, SONALI A. PATANGE, Alka Gandhi
Integrative Diabetes and Cardiovascular Diseases (2019), pp. 76-83
Open Access
